Evaluation of the efficacy and tolerance of rokitamycin in treating infections of the lower respiratory tract.

A trial was conducted to evaluate the efficacy and tolerance of rokitamycin in 30 patients (23 male, seven female; mean age, 59.9 years ± 1.7 SE) affected by infective disorders of the lower-respiratory tract. Rokitamycin was available in 400-mg tablets; 18 patients were given 800 mg per day, and the remaining 12 were treated with 1,200 mg per day. Treatment lasted between seven and 14 days. The germs that were initially sensitive to rokitamycin were completely eradicated, in particular, four of four Haemophilus influenzae, three of three Streptococcus pneumoniae, two of two Streptococcus pyogenes, three of three Staphylococcus aureus, two of two Staphylococcus epidermidis, and two of two Mycoplasma pneumoniae. The amount of sputum was considerable reduced, and body temperature and erythrocyte sedimentation rate values were also significantly lowered. The pneumology symptomatology was efficiently checked by rokitamycin, which proved to be well tolerated in general. In conclusion, rokitamycin may be considered to be an unfailingly effective and well-tolerated antibiotic for treating patients with infectious disorders of the lower-respiratory tract.